The epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody, cetuximab, is a breakthrough in targeted therapy for head and neck cancers, especially among patients with recurrent or metastatic disease [1]. The gene discussed is EGFR; the disease is head and neck cancer.